Related Experiment Video
Updated: Aug 14, 2026

A Low Mortality Rat Model to Assess Delayed Cerebral Vasospasm After Experimental Subarachnoid Hemorrhage
Published on: January 17, 2013
Role of MAPK in chronic cerebral vasospasm
K Aoki1, A Y Zubkov, R E Tibbs
1Department of Neurosurgery, University of Mississippi Medical Center, Jackson 39216-4505, USA.
Abstract:
This study was undertaken to investigate the role of p44/42 MAPK in a dog double hemorrhage model of subarachnoid hemorrhage (SAH), and whether MEK inhibitors can alter the degree of SAH-induced vasoconstriction. The diameter of the basilar artery, which was compared with day 0 angiogram, decreased gradually in a time-dependent manner from day 3 (80%), day 5 (68%) through day 7 (53.5%). The level of MAPK (p44/42) immunoprecipitation peaked on day 3 and remained enhanced through day 7 (P < 0.05). MEK inhibitor PD98059 significantly reduced p44/42 MAPK immunoprecipitation and significantly reversed vasospasm and increased residual diameter to 79.0% on day 7. These results demonstrated that p44/42 MAPK kinase is involved in the pathogenesis of cerebral vasospasm. The MEK inhibitor PD98059 might be useful in the treatment of vasospasm.
Insights
p44/42 mitogen-activated protein kinase (MAPK) plays a key role in subarachnoid hemorrhage (SAH)-induced cerebral vasospasm. MEK inhibitor PD98059 effectively reversed this vasospasm in a canine model.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Subarachnoid hemorrhage (SAH) can lead to delayed cerebral vasospasm, a significant cause of morbidity and mortality.
- The precise molecular mechanisms underlying SAH-induced vasospasm are not fully understood.
Purpose of the Study:
- To investigate the involvement of p44/42 mitogen-activated protein kinase (MAPK) in canine SAH.
- To determine if MEK inhibitors can mitigate SAH-induced cerebral vasoconstriction.
Main Methods:
- A double hemorrhage model of SAH was established in dogs.
- Basilar artery diameter was measured via angiogram over 7 days.
- p44/42 MAPK levels were assessed using immunoprecipitation.
- The effect of MEK inhibitor PD98059 on vasospasm and MAPK levels was evaluated.
Main Results:
- SAH induced a time-dependent decrease in basilar artery diameter, indicative of vasospasm.
- p44/42 MAPK levels significantly increased following SAH and remained elevated.
- PD98059 treatment significantly reduced p44/42 MAPK activation.
- PD98059 administration significantly reversed vasospasm, increasing residual basilar artery diameter.
Conclusions:
- p44/42 MAPK signaling is implicated in the pathogenesis of cerebral vasospasm after SAH.
- MEK inhibitor PD98059 demonstrates therapeutic potential for treating SAH-induced vasospasm.
Related Concept Videos
MAPK Signaling Cascades
Vascular Spasm
Ischemic Stroke ll: Pathophysiology
Cerebral Edema ll: Pathophysiology

